Compare · ALB vs CDXS
ALB vs CDXS
Side-by-side comparison of Albemarle Corporation (ALB) and Codexis Inc. (CDXS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALB and CDXS operate in Major Chemicals (Industrials), so they compete in similar markets.
- ALB is the larger of the two at $17.67B, about 74.6x CDXS ($236.8M).
- Over the past year, ALB is up 140.5% and CDXS is up 9.0% - ALB leads by 131.4 points.
- ALB has been more active in the news (4 items in the past 4 weeks vs 1 for CDXS).
- ALB has more recent analyst coverage (25 ratings vs 12 for CDXS).
- Company
- Albemarle Corporation
- Codexis Inc.
- Price
- $149.78-3.75%
- $2.60+2.36%
- Market cap
- $17.67B
- $236.8M
- 1M return
- -24.51%
- +0.39%
- 1Y return
- +140.46%
- +9.01%
- Industry
- Major Chemicals
- Major Chemicals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2010
- News (4w)
- 4
- 1
- Recent ratings
- 25
- 12
Albemarle Corporation
Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Lithium, Bromine Specialties, and Catalysts. The Lithium segment offers lithium compounds, including lithium carbonate, lithium hydroxide, lithium chloride, and lithium specialties; and reagents, such as butyllithium and lithium aluminum hydride for use in lithium batteries for consumer electronics and electric vehicles, high performance greases, thermoplastic elastomers for car tires, rubber soles, plastic bottles, catalysts for chemical reactions, organic synthesis processes in the areas of steroid chemistry and vitamins, life sciences, pharmaceutical industry, and other markets. It also provides cesium products for the chemical and pharmaceutical industries; zirconium, barium, and titanium products for pyrotechnical applications; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services. The Bromine Specialties segment offers bromine and bromine-based fire safety solutions; specialty chemicals, including elemental bromine, alkyl and inorganic bromides, brominated powdered activated carbon, and other bromine fine chemicals for use in chemical synthesis, oil and gas well drilling and completion fluids, mercury control, water purification, beef and poultry processing, and other industrial applications; and other specialty chemicals, such as tertiary amines, biocides, disinfectants, and sanitizers. The Catalysts segment provides hydroprocessing, isomerization, and akylation catalysts; fluidized catalytic cracking catalysts and additives; and organometallics and curatives. The company serves the energy storage, petroleum refining, consumer electronics, construction, automotive, lubricants, pharmaceuticals, crop protection, and custom chemistry services markets. Albemarle Corporation was founded in 1887 and is headquartered in Charlotte, North Carolina.
Codexis Inc.
Codexis, Inc. discovers, develops, and sells biocatalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
Latest ALB
- Albemarle Corporation filed SEC Form 8-K: Leadership Update
- SEC Form SD filed by Albemarle Corporation
- Albemarle upgraded by Vertical Research with a new price target
- Chairman & CEO Masters J Kent sold $3,011,766 worth of shares (16,393 units at $183.72), decreasing direct ownership by 16% to 87,519 units (SEC Form 4)
- SEC Form S-8 filed by Albemarle Corporation
- Albemarle Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 10-Q filed by Albemarle Corporation
- Albemarle Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Albemarle Announces Quarterly Common Stock Dividend
- Albemarle downgraded by Rothschild & Co Redburn with a new price target
Latest CDXS
- Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA
- SEC Form 10-Q filed by Codexis Inc.
- Codexis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Codexis Reports First Quarter 2026 Financial Results
- Codexis to share RNA manufacturing advances at TIDES USA
- SEC Form DEFA14A filed by Codexis Inc.
- SEC Form DEF 14A filed by Codexis Inc.
- Codexis to Report First Quarter 2026 Financial Results on May 7
- SEC Form 8-K filed by Codexis Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Codexis Inc.